OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity

Not Applicable

Recruiting

• Conditions: Vision Loss Night; Vision Disorders
• Interventions: Drug: 0.75% Phentolamine Ophthalmic Solution; Drug: Placebo

• Registration Number: NCT07140783
• Lead Sponsor: Ocuphire Pharma, Inc.

Brief Summary

The goal of this clinical trial is to learn if Phentolamine Ophthalmic Solution works to treat adults that have had keratorefractive surgery and have decreased visual acuity under mesopic conditions. It will also learn about the safety of Phentolamine Ophthalmic Solution. The main questions it aims to answer are:

Researchers will compare Phentolamine Ophthalmic Solution to a placebo (a look-alike substance that contains no drug) to see if Phentolamine Ophthalmic Solution works to improve vision in low light conditions.

Participants will:

Take Phentolamine Ophthalmic Solution or a placebo drop every day for 2 weeks Visit the clinic once every week for 2 weeks for checkups and tests Keep a diary of when they instill the study medication each evening

Detailed Description

OPI-NXYDLD-303 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-MASKED STUDY OF THE SAFETY AND EFFICACY OF POS (0.75% PHENTOLAMINE OPHTHALMIC SOLUTION) IN PARTICIPANTS WHO HAVE PREVIOUSLY HAD KERATOREFRACTIVE SURGERY AND HAVE DECREASED VISUAL ACUITY UNDER MESOPIC CONDITIONS

Study Timeline

• Study First Submitted: 2025-08-22
• Study First Submitted QC: 2025-08-22
• Study First Posted: 2025-08-26
• Status Verified: 2025-09
• Study Start: 2025-09-02
• Last Update Submitted: 2025-09-11
• Last Update Posted: 2025-09-12
• Primary Completion: 2026-03
• Study Completion: 2026-03-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

1. Males or females ≥ 18 years of age

2. Previous history (>6 months prior to Screening) of keratorefractive surgery (eg, PRK, LASIK, SMILE, and RK/astigmatic keratotomy [AK]/limbal-relaxing incisions [LRI]) in one or both eyes and have participant-reported night vision disturbances (eg, glare, halos, and/or starbursts). Symptoms must have been first noted within 2 months following keratorefractive surgery

3. Able to independently comply with all protocol-mandated procedures and to attend all scheduled office visits

4. Able and willing to give written consent to participate in this study

5. Able to self-administer study medication

   Inclusion criteria #6, #7, and #8 must all be met in the same eye:

6. PD ≥ 5 mm under mesopic conditions in at least 1 eye. This test may be repeated once, following an additional 5 min of dark adaptation to the mesopic light conditions if the initial results do not meet this criterion

7. mLCVA ≤ 30 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (20/63 Snellen or worse) in at least 1 eye using the Precision Vision Illuminator Cabinet with 5% translucent contrast chart and a mesopic filter at 4 m

8. ≥ 10 ETDRS letters improvement in mLCVA in at least 1 eye during illumination of the contralateral eye with a Brightness Acuity Tester (BAT) system on the low setting using the Precision Vision Illuminator Cabinet with 5% translucent contrast chart and a mesopic filter at 4 m

Exclusion Criteria

Ophthalmic (in either eye unless otherwise noted):

1. Prior unresolved dry eye diagnosis, taking prescription medication for dry eye (eg, drops, nasal sprays [Tyrvaya®], etc.), or taking artificial tear drops routinely for dry eye

2. Prior history of fluctuating vision

3. Clinically significant ocular disease as deemed by the Investigator (eg, untreated visually significant cataract, glaucoma, corneal edema, uveitis, severe keratoconjunctivitis sicca, retina degeneration, loss of visual field due to glaucoma or stroke, branch retinal vein occlusion, retina flare) that might interfere with the study

4. History or presence of corneal endothelial dystrophy (eg, Fuchs' dystrophy or presence of guttae)

5. Known hypersensitivity to any topical alpha-adrenoceptor antagonists

6. Known allergy or contraindication to any component of the vehicle formulation

7. History of cauterization of the punctum or punctal plug (silicone or collagen) insertion or removal in the study eye

8. Pseudophakic participants with extended depth-of-focus or multifocal intraocular lenses (IOLs)

9. Ocular trauma, ocular surgery (eg, IOLs), or laser procedure (eg, LASIK, PRK, SMILE, and RK/AK/LRI) within 6 months prior to Screening

10. Use of any topical prescription or over-the-counter (OTC) ophthalmic medications of any kind (including artificial tear drops) within 7 days prior to Screening until study completion, with the exception of lid scrubs with OTC products (eg, OCuSOFT® lid scrub, SteriLid®, baby shampoo, etc.)

11. Recent or current evidence of ocular infection or inflammation (such as current evidence of clinically significant blepharitis, conjunctivitis, or a history of herpes simplex keratitis or herpes zoster keratitis at Screening). Participants must be symptom free for at least 7 days prior to Screening

12. History of diabetic retinopathy, diabetic macular edema, or dry or wet macular degeneration in the study eye

13. History of any traumatic (surgical or nonsurgical) or nontraumatic condition affecting the pupil or iris (eg, irregularly shaped pupil, neurogenic pupil disorder, iris atrophy, iridotomy, iridectomy, etc.)

14. Unwilling or unable to discontinue use of contact lenses at least 1 hour prior to Screening for soft contact lenses or at least 8 hours prior to Screening for hard gas-permeable contact lenses, and at least 8 hours (for both types of lenses) prior to all other office visits

15. Previously undiagnosed dry eye, at the determination of the Investigator. Dry eye diagnosis should be based on one of the following dry eye test results: tear break-up time < 5 seconds, or corneal fluorescein staining ≥ Grade 2 in the inferior zone or ≥ Grade 1 in the central zone using the National Eye Institute scale

    Systemic:

16. Known hypersensitivity or contraindication to alpha- and/or beta-adrenoceptor antagonists

17. Clinically significant systemic disease (eg, severe diabetes, myasthenia gravis, cancer, hepatic, renal, endocrine, or cardiovascular disorders) that might interfere with the study

18. Initiation of treatment with or any changes to the current dosage, drug, or regimen of any systemic adrenergic or cholinergic drugs within 7 days prior to Screening or during the study

19. Participation in any investigational study within 30 days prior to Screening or during the study

20. Participation in any investigational study using POS

21. Females of childbearing potential who are pregnant, nursing, planning a pregnancy during the study, or not using a medically acceptable form of birth control. Acceptable methods include the use of at least one of the following: intrauterine device, hormonal contraception (oral, injection, patch, implant, ring), barrier with spermicide (condom, diaphragm), or abstinence. A female is considered to be of childbearing potential unless she is 1 year postmenopausal or 3 months post-surgical sterilization. All females of childbearing potential, including those post-tubal ligation, must have a negative urine pregnancy test result at each visit

22. Resting HR outside 50 to 110 beats per min at Screening. HR may be repeated only once if outside the specified range, following at least a 5-min rest period in the sitting position

23. Hypertension with resting diastolic BP > 105 mmHg or systolic BP > 160 mmHg at Screening. BP may be repeated only once if outside the specified range, following at least a 5-min rest period in the sitting position

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
0.75% Phentolamine Ophthalmic Solution	0.75% Phentolamine Ophthalmic Solution	0.75% Phentolamine Ophthalmic Solution
Placebo - Phentolamine Ophthalmic Solution vehicle	Placebo	Placebo-phentolamine ophthalmic solution vehicle

Primary Outcome Measures

Name	Time	Method
Percent of participants with >= 15 ETDRS letters (>= 3 lines) improvement in the study eye in mLCVA compared to Baseline (Day1 pre-dose) at Day 15	Day 15	To evaluate the efficacy of POS to improve mLCVA in subjects with previous keratorefractive surgery

Trial Locations

Locations (23)

Arizona Eye Care; 🇺🇸 Chandler, Arizona, United States

Carrot Eye Center; 🇺🇸 Mesa, Arizona, United States

Eye Doctors of Arizona; 🇺🇸 Phoenix, Arizona, United States

MRB Eye Care Consultants; 🇺🇸 Scottsdale, Arizona, United States

Global Research Management; 🇺🇸 Glendale, California, United States

Gordon Schanzlin New Vision; 🇺🇸 La Jolla, California, United States

Eye Research Foundation; 🇺🇸 Newport Beach, California, United States

California Eye Specialists Medical Group; 🇺🇸 Pasadena, California, United States

NVISION Clinical Research; 🇺🇸 San Diego, California, United States

Scripps Poway Eyecare and Optometry; 🇺🇸 San Diego, California, United States

Scroll for more (13 remaining)